0.675
price down icon4.67%   -0.0331
after-market After Hours: .70 0.025 +3.70%
loading
Prelude Therapeutics Inc stock is traded at $0.675, with a volume of 185.89K. It is down -4.67% in the last 24 hours and down -8.78% over the past month. Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.7081
Open:
$0.7001
24h Volume:
185.89K
Relative Volume:
0.75
Market Cap:
$37.23M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.3792
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-15.59%
1M Performance:
-8.78%
6M Performance:
-66.25%
1Y Performance:
-85.76%
1-Day Range:
Value
$0.6561
$0.705
1-Week Range:
Value
$0.6561
$0.87
52-Week Range:
Value
$0.63
$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name
Name
Prelude Therapeutics Inc
Name
Phone
(302) 467-1280
Name
Address
175 INNOVATION BOULEVARD, WILMINGTON
Name
Employee
131
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
PRLD's Discussions on Twitter

Compare PRLD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRLD
Prelude Therapeutics Inc
0.675 37.23M 0 -131.52M -107.56M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-19-24 Upgrade H.C. Wainwright Neutral → Buy
Jun-20-24 Downgrade Barclays Equal Weight → Underweight
Mar-13-24 Initiated JMP Securities Mkt Outperform
Feb-20-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-19-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-21-22 Downgrade BofA Securities Neutral → Underperform
Sep-09-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-29-22 Initiated Jefferies Buy
Mar-15-22 Downgrade BofA Securities Buy → Neutral
Feb-28-22 Downgrade Barclays Overweight → Equal Weight
Oct-08-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-27-21 Upgrade BofA Securities Neutral → Buy
Apr-26-21 Initiated H.C. Wainwright Buy
Mar-09-21 Initiated Barclays Overweight
Nov-20-20 Downgrade BofA Securities Buy → Neutral
Oct-20-20 Initiated BofA Securities Buy
Oct-20-20 Initiated Goldman Neutral
Oct-20-20 Initiated Morgan Stanley Equal-Weight
View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 29, 2025

Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 25, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock - Investing.com India

Mar 25, 2025
pulisher
Mar 24, 2025

Prelude Therapeutics CEO Vaddi Krishna acquires $14,909 in stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 19, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Prelude Therapeutics CEO Krishna Vaddi increases stake with $29,459 stock purchase By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Prelude Therapeutics’ SWOT analysis: biotech stock faces mixed outlook amid clinical trials - Investing.com Australia

Mar 17, 2025
pulisher
Mar 16, 2025

NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial - MyChesCo

Mar 16, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Prelude therapeutics CEO Krishna Vaddi acquires $69,564 in shares - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements - MyChesCo

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Prelude Therapeutics Reports 2024 Financial Results - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Inc SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

PRLDPrelude Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MyChesCo

Mar 09, 2025
pulisher
Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025
pulisher
Mar 06, 2025

Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo

Mar 05, 2025
pulisher
Mar 05, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo

Mar 05, 2025
pulisher
Mar 04, 2025

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance

Mar 04, 2025
pulisher
Feb 28, 2025

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

PRLD stock touches 52-week low at $0.79 amid market challenges - Investing.com

Feb 27, 2025
pulisher
Feb 26, 2025

Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Context Therapeutics Grants Stock Options to New Employees - MyChesCo

Feb 25, 2025
pulisher
Feb 18, 2025

Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MyChesCo

Feb 18, 2025
pulisher
Feb 13, 2025

Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MyChesCo

Feb 13, 2025
pulisher
Feb 13, 2025

Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly

Feb 12, 2025
pulisher
Feb 11, 2025

Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Feb 11, 2025
pulisher
Feb 07, 2025

Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo

Feb 07, 2025
pulisher
Feb 05, 2025

Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks

Feb 05, 2025

Prelude Therapeutics Inc Stock (PRLD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Prelude Therapeutics Inc Stock (PRLD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Vaddi Krishna
CEO
Mar 25 '25
Buy
0.69
675,000
467,438
1,999,296
Vaddi Krishna
CEO
Mar 21 '25
Buy
0.73
15,000
10,959
1,324,296
Vaddi Krishna
CEO
Mar 20 '25
Buy
0.73
5,416
3,950
1,309,296
Vaddi Krishna
CEO
Mar 14 '25
Buy
0.75
29,999
22,631
1,294,774
Vaddi Krishna
CEO
Mar 17 '25
Buy
0.75
9,106
6,829
1,303,880
Vaddi Krishna
CEO
Mar 13 '25
Buy
0.72
50,000
35,820
1,264,775
Vaddi Krishna
CEO
Mar 12 '25
Buy
0.71
47,500
33,744
1,214,775
Vaddi Krishna
CEO
Dec 31 '24
Buy
1.21
5,000
6,044
142,553
Vaddi Krishna
CEO
Dec 30 '24
Buy
1.20
10,000
12,000
137,553
Combs Andrew
Chief Chemistry Officer
Dec 23 '24
Buy
1.37
60,000
82,002
377,623
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):